Dr. Selkoe is a Founding Scientific Advisory Board Member of Satori Pharmaceuticals. He has been setting the pace of Alzheimer's disease research for the last 25 years. He oversees a team of researchers as the Vincent and Stella Coates Professor of Neurologic Diseases and the Co-director of the Center for Neurologic diseases at the Brigham and Women's Hospital, an affiliate of Harvard Medical School.
Research from his lab helped uncover the protein nature of the amyloid plaques, the hallmark of Alzheimer's, along with the proposed biological mechanism that generates the formation Of the plaques. This insightful research has resulted in some 250 peer-reviewed publications, including numerous articles in top research journals such as Science and Nature.
More importantly, Dr. Selkoe's research has translated into the clinic where ongoing drug trials are beginning to treat Alzheimer's patients with therapies based in part on his ideas and work Dr. Selkoe's achievements have not gone unnoticed.
In 2002, he received the Dr. A.H. Heinenken Prize for Medicine for "his invaluable contribution to the development of the molecular study of disease of the brain, in particular Alzheimer's disease". Additional accolades include the Mathilde Solowey Award in Neurosciences from the NIH, the Pioneer Award from the Alzheimer's Association USA, and a recent appointment as a Fellow of the American Association for the Advancement of Science.
Dr. Selkoe's research has also generated insights into the function of specific cell proteins that will have a far reaching impact on other areas of biology. Dr. Selkoe also serves as a Non-Executive Director of Elan Pharmaceuticals, and was a founder of Athena.